Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Oruka Therapeutics IncORKA | $56.37 | Strong Buy | $75.00 | +33.05% | 20 hours ago | |
Analyst RankingTop 15% #772 out of 5238 analysts Average Return+11.37% Win Rate47%42 out of 89 Risk vs RewardPoor Good Analyst ColorUBS's Michael Yee raised their price target on Oruka Therapeutics (NASDAQ: ORKA) by 50% from $50 to $75 on 2026/04/06. The analyst maintained their Strong Buy rating on the stock. Yee said their price target hike was catalyzed when Oruka Therapeutics announced it expects to report 16-week efficacy data for ORKA-001 in psoriasis in Q2 2026. The analyst said they are positive on the stock price setup ahead of the readout because they think the data will be strong, with PASI-100 rates in or above the 40% range, comparable or better than Skyrizi's 16-week efficacy in Phase 3. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.